drugset / Trial / NCT00411164

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

NCT00411164

Phase 3 Completed 990 enrolled Alza Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to compare the analgesic (a drug that relieves pain) effectiveness and safety of OROS hydromorphone HCI (slow release) 8 mg and 16 mg to placebo (no drug) in patients with osteoarthritis (OA).

Timeline

Start
2003-11
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 8 mg Oral
Subject Hydromorphone Other / unclassified 16 mg Oral